Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.49 |
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27160050 | 0.88 | PARP11 (0.48) | PARP11PARP10PARP1MAPKAPK2MAPK9 | |
| SCHEMBL31079116 | 0.87 | PARP10 (0.43) | PARP11PARP10MAPKAPK2MAPK9MAPK1 | |
| SCHEMBL31079103 | 0.85 | PARP10 (0.55) | PARP11PARP10PARP1MAPKAPK2MAPK9 | |
| SCHEMBL29964579 | 0.84 | MAPKAPK2 (0.42) | PARP11PARP10MAPKAPK2MAPK9MAPK1 | |
| SCHEMBL29965201 | 0.83 | PARP10 (0.47) | PARP11PARP10PARP1MAPKAPK2MAPK9 | |
| SCHEMBL31079171 | 0.81 | PARP10 (0.42) | PARP11PARP10MAPKAPK2MAPK9MAPK1 | |
| SCHEMBL31079164 | 0.81 | PARP11 (0.43) | PARP11PARP10PARP1MAPKAPK2MAPK9 | |
| SCHEMBL31079366 | 0.81 | MAPK1 (0.55) | PARP11PARP10MAPKAPK2MAPK9MAPK1 | |
| SCHEMBL29964506 | 0.81 | CDK4 (0.42) | PARP11PARP10MAPKAPK2MAPK9MAPK1 | |
| SCHEMBL31079102 | 0.80 | MAPK1 (0.43) | PARP11PARP10MAPKAPK2MAPK9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | PARP11 1176/4885PARP10 2072/4885PARP1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.